News

Newsmogrifydigital2026-02-25T11:17:26+00:00

FEATURED

CONTENT

Mogrify extends Series A financing to $46 million USD

Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.

Latest

NEWS

Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Business Weekly Awards 2020

Mark Cavanagh2025-08-20T14:54:06+00:0018th September 2020|

Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019

Mark Cavanagh2022-05-09T10:43:59+00:005th December 2019|

Mogrify wins Seed Stage Finance Raise of the Year at 2019 European Lifestars Awards

Mark Cavanagh2022-05-09T10:44:09+00:0020th November 2019|

Mogrify named ‘The One to Watch’ at Cambridge Independent Science and Technology Awards 2019

Mark Cavanagh2022-05-09T10:44:15+00:0031st October 2019|

Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies

Mark Cavanagh2025-08-20T14:47:31+00:0014th October 2019|

Mogrify strengthens team and relocates to the Bio-Innovation Centre, TusPark Cambridge

mogrifydigital2022-05-09T10:44:57+00:0020th May 2019|

Load More Posts

Latest

Resources

VIEW ALL RESOURCES

VIEW ALL MEDIA FEATURES